Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02021721|
Recruitment Status : Recruiting
First Posted : December 27, 2013
Last Update Posted : May 2, 2018
Hypothesis: To identify new gene mutations that can be related to patients with idiopathic male factor infertility.
Primary Objective: To detect possible genetic abnormalities in families with more than one sibling with male infertility.
Secondary Objective: To evaluate using next generation DNA sequencing in cases of infertility
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
- Next generation sequencing [ Time Frame: 1 hour ]Use next generation sequencing to discover novel genes
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02021721
|Contact: Grace Mammen, BA, CCRPfirstname.lastname@example.org|
|Contact: Amal Robay, PhD, CCRPemail@example.com|
|Hamad Medical Corporation||Recruiting|
|Contact: Alya Al-Shakaki +974-492-8445 firstname.lastname@example.org|
|Sub-Investigator: Amal Robay, PhD|
|Principal Investigator:||Ronald Crystal, MD||Weill Medical College of Cornell University|
|Principal Investigator:||Haitham El Bardisi, MD||Hamad Medical Corporation|